Daiichi Sankyo invests in its production facility in Alsace!

Daiichi Sankyo, the first European subsidiary of the Japanese global pharmaceutical group, is to invest 17 million euros in its site located in Altkirch. The group is present in more than fifty countries and is Japan’s number three company in the pharmaceutical industry. Its parent company is based in Tokyo and the American company American Regent is its only shareholder.

The site of Altkirch is dedicated to the manufacture of active ingredients for veterinary and human medicines. This investment in the production capacity of active ingredients for the veterinary industry is the most important one on the site since its creation in 1975. The expansion project will be executed in two phases and is accompanied by the creation of 15 jobs. It responds to a strong demand from American Regent and aims to increase the production capacity from 13 batches of 70 kg to 27 batches of finished products per year with no interruption of activity.

Supported locally, by the development agency ADIRA in particular, the company is well rooted in the region and benefits from a visibility made possible both by local partnerships and regional stakeholders. The purpose is to enable optimal sharing of practices and to discuss development projects, which, in light of its current expansion, definitely augur well for the company!